Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5- fluorouracil infusion and radiation therapy

Cancer

Volumn 78, Issue 2, 1996, Pages 217-225

  De Marsh, Robert W ^a   Chu, Nei Min ^a   Vauthey, Jean Nicholas ^a   Mendenhall, William M ^a   Lauwers, Gregory Y ^a   Bewsher, Carol ^a   Copeland, Edward M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

chemotherapy; chronobiology; circadian; preoperative; radiotherapy; rectal carcinoma

Indexed keywords

FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHRONOPHARMACOLOGY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM PERMISSIBLE DOSE; PHASE 2 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RECTUM CARCINOMA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANAL CANAL; ANTIMETABOLITES, ANTINEOPLASTIC; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG TOLERANCE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PREOPERATIVE CARE; RADIOTHERAPY DOSAGE; RECTAL NEOPLASMS; REMISSION INDUCTION; SURVIVAL RATE;

EID: 0029681983     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960715)78:2<217::AID-CNCR5>3.0.CO;2-I     Document Type: Article

References (44)

1. American Cancer Society. Cancer Statistics 1995. CA Cancer J Clin 1995;45:12.
2. Mendenhall WM, Souba WW, Bland KI, Million RR, Copeland EM. Preoperative irradiation and surgery for initially unresectable adenocarcinoma of the rectum. Am Surg 1992;58(7):423-9.
3. Doseretz DE, Gunderson LL, Hedberg S, Hoskins B, Blitzer P, Shipley W, et al. Preoperative irradiation for unresectable rectal and rectosigmoid carcinoma. Cancer 1983;52:814-8.
4. Gerard A, Buyse M, Nordlinger B, Loygue J, Pene F, Kempf P, et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer - final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg 1988;208:606-14.
5. Mendenhall WM, Bland KI, Copeland EM III, Summers GE, Pfaff WM, Souba WW, et al. Does preoperative radiation therapy enhance the probability of local control and survival in high-risk distal rectal cancer? Ann Surg 1992;215(6):696-705.
6. Byfield J, Calabro-Jones P, Klisak I, Kulhanian F. Pharmacologie requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and x-rays. Int J Radiat Oncol Biol Phys 1982;8:1923-33.
7. Nakajima Y, Miyamoto T, Tanabe M. Enhancement of mammalian cell killing by 5-fluorouracil in combination with x-rays. Cancer Res 1979;39:3762-7.
8. Smalley SR, Kimler BF, Evans RG. 5-fluorouracil modulation of radio-sensitivity in cultured human carcinoma cells. Int J Radiat Oncol Biol 1991;20:207-11.
9. Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham D, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer. Results from NSABP protocol R-01. J Natl Cancer Inst 1988;80(1):21-9.
10. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, et al. Effective surgical adjuvant therapy for high risk rectal carcinoma. N Engl J Med 1991;324(11):709-15.
11. O'Connell MJ, Martenson JA, Wieand HS, Krook J, Macdonald J, Haller D, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502-7.
12. Goldie JH, Goldman AS. A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-33.
13. Fisher B, Gunduz N, Saffer E. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastasis. Cancer Res 1983;43:1488-92.
14. DeWys WD. Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic grow-retarding factors. Cancer Res 1972;32:374-9.
15. Minsky BD, Cohen AM, Kemeny N, Enker WE, Kelsen DP, Reichman B, et al. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high dose leucovorin chemotherapy. J Clin Oncol 1992;10(1):79-84.
16. Chari RS, Tyler DS, Anscher MS, Russell L, Clary BM, Hathorn J, et al. Preoperative radiation and chemotherapy in the treatment of adeno-carcinoma of the rectum. Ann Surg 1995;221:778-87.
17. Picciocchi A, Coco C, Magistrelli P, Roncolini G, Netri G, Mattana C, et al. Concomitant preoperative radiochemotherapy in operable locally advanced rectal cancer. Dis Colon Rectum 1994;37(2 Suppl):69-72.
18. Minsky BD, Cohen A, Enker W, Kelsen D, Kemeny N, Ilson D, et al. Preoperative 5-fluorouracil, low dose leucovorin and concurrent radiation therapy for rectal cancer. Cancer 1994;73(2):273-80.
19. Rich T, O'Connell M, Martenson J, Wieand H, Krook J, MacDonald J, et al. Improved therapeutic ratio with protracted venous infusion (PVI) 5-FU during postoperative external beam radiation therapy for high-risk cancer. Int J Radiat Oncol Biol Phys 1992;27(Suppl 1):245-6.
20. Chen ET, Mohiuddin M, Brodovsky H, Fishbein G, Marks G. Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int J Radiat Oncol Biol Phys 1994;30(1):169-75.
21. Shumate CR, Rich TA, Skibber JM, Ajani JA, Ota DM. Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. Cancer 1993;71(11):3690-6.
22. Levi F, Soussan A, Adam R, Caussanel JP, Metzger G, Misset JL. Programmable in time pumps for chronotherapy of patients with colorectal cancer with 5 day circadian modulated venous infusion of 5-fluorouracil [abstract]. Proc Am Soc Clin Oncol 1989;8:111; p. 429.
23. Agaliotis D, Marsh R de W. The University of Florida experience with chronobiologic cancer therapy. J Infusional Chemo 1992;2(2):76-8.
24. Bjarnason GA, Marsh R, Chu N-M, Hrushesky W, Kerr I. Phase II study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in patients with metastatic colorectal cancer. Biol Rhy Res 1995;26(4):31.
25. Bjarnason GA, Hrushesky WJM, Diasio R, Harris J, Marsh R, Huben R, et al. Flat versus circadian modified 14 day infusion of FUDR for advanced renal cell cancer: a phase-III study. Proc Am Soc Clin Oncol 1994;13:233; 718.
26. Beahrs O, Henson D, Hutter R, Kennedy B, eds. Manual for staging of cancer. 4th edition; Philadelphia: JB Lippincott, 1992, p. 97.
27. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer 1994;73:2680-6.
28. Heald RJ, Husband EM, Ryall RDH. The mesorectum in rectal cancer surgery - the clue to pelvic recurrence? Br J Surg 1982;69:613-6.
29. MacMillan WE, Wobery WH, Welling PG. Pharmacokinetics of 5-fluorouracil in humans. Cancer Res 1978;38:3479-82.
30. Hansen RM, Quebbeman E, Anderson T. 5-Fluorouracil by protracted venous infusion. Oncology 1989;46:245-50.
31. Shackney SE. Cell kinetics and cancer chemotherapy. In: Calabresi P, Schein PS, Rosenberg SA editors. Medical Oncology. New York: MacMillan, 1985:41-60.
32. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal cancer. J Clin Oncol 1989;7(10):1407-18.
33. O'Dwyer PJ, Paul AR, Walczak J, Weiner LM, Litwin S, Comis RL. Phase II study of biochemical modulation of fluorouracil by low dose PALA in patients with colorectal cancer. J Clin Oncol 1990;8:1497-503.
34. Wadler S, Wersto R, Weinberg V, Thompson D, Schwartz EL. Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res 1990;50:5735-9.
35. Weinerman B, Shah A, Fields A, Cripps K, Wilson K, McCormick R, et al. Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer. Am J Clin Oncol 1992;15(6)518-23.
36. Milano G, Etienne MC, Renee N, Thyss A, Schneider M, Ramaioli A, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994;12(6):1291-5.
37. Hryniuk WM, Figueredo A, Goodyear M. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 1987;14(4):3-11.
38. Buchi KN, Moore JG, Rubin NH. Circadian cellular proliferation measurements in human rectal mucosa. Chronobiologia 1987;14:155-6.
39. Buchi KN, Rubin N, Moore JG. Circadian rhythm of cellular proliferation in the human rectal mucosa. In: Reinberg A, Smolensky M, Labreque G, editors. Annual review of chronopharmacology. Volume 5. New York: Pergamon Press, 1988:355.
40. Harris BE, Song R, He Y-J, Soong SJ, Diasio RB. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase: possible relevance to fluoropyrimidine chemotherapy. Biochem Pharmacol 1988;37:4759-62.
41. Tuchman M, Roemeling R, Lanning R, Sothern RB, Hrushesky WJM. Source of variability of dihydropyrimidine dehydrogenase activity in human blood mononuclear cells. In: Reinberg A, Smolensky M, Labrecque G, editors. Annual review of chronopharmacology. Volume 5. New York: Pergamon Press, 1988:399-402.
42. Fleming RA, Milano G, Thyss A, Etienne M-C, Renee N, Schneider M, et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 1992;52:2899-902.
43. Milsom JW, Lavery IC, Stolfi VM, Czyrko C, Church JM, Oakley JR, et al. The expanding utility of endoluminal ultrasonography in the management of rectal cancer. Surgery 1992;112:832-41.
44. de Lange EE, Fechner RE, Edge SB, Spaulding CA. Preoperative staging of rectal carcinoma with MR imaging: surgical and histopathologic correlation. Radiology 1990;176:623-8.